Sunday 11 October 2026 Export all VXRT data to Excel Powerpack

VAXART, INC.

VXRT Healthcare Biotechnology

VAXART, INC.’s revenue for fiscal 2025 (year ended December 2025) was $237.3 million, up 726.7% from fiscal 2024. In the quarter to June 2026, revenue fell 31.6%, EPS grew 14.3% and free cash flow grew 117.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

0.43 0.00 0.00%
Market cap
$92.4M
P/E
2.8×
Fwd P/E
2.1×
Dividend yield
—
F-score
6/9
Altman Z
−1.06
Beneish M
3.73
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
6 6 6 4

+8 more TTM periods

ROE
66.97% 53.10% 22.26% (106.52%)
ROA
23.44% 21.91% 9.26% (26.99%)
ROIC
134.59% 72.11% 47.09% 0.00%
Return on Tangible Assets
78.61% 62.15% 29.79% 110.55%
Average Days of Receivables
70.57 82.21 78.99 211.67
Free Cash Flow per Share
0.14 0.06 0.03 (0.13)
Free Cash Flow
33.40 14.80 7.57 (30.48)
Other line items

Show all line items

Columns are period end dates